Description

Thermo Fisher’s $12.14 Billion Quarter — Can 15% EPS Growth Continue?

Thermo Fisher Scientific Inc. reported third quarter 2026 results reflecting a 9% increase in revenue to $12.14 billion, with organic growth accounting for 6% of that increase. The company’s GAAP diluted earnings per share rose 9% to $4.64, while adjusted EPS, which excludes certain acquisition-related and restructuring expenses, grew by 15% to $6.68. Operating income demonstrated a 17% rise on a GAAP basis, leading to an improved operating margin of 18.6% compared to 17.4% in the prior year. Adjusted operating income grew 15% to nearly $3 billion, with adjusted operating margins expanding modestly from 23.3% to 24.5%. These results were supported by the execution of Thermo Fisher’s growth strategy, including the launch of several innovative products such as the Orbitrap Isora mass spectrometer and the Ion 560 Chip sequencing chip, aimed at enhancing workflow efficiencies and enabling advanced research in environmental, life sciences, and genomic fields.